株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

高血圧症 : パイプライン分析

Hypertension - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232783
出版日 ページ情報 英文 551 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.93円で換算しております。
Back to Top
高血圧症 : パイプライン分析 Hypertension - Pipeline Review, H2 2016
出版日: 2016年12月21日 ページ情報: 英文 551 Pages
概要

高血圧症は、動脈が血圧を持続的に上げた状態を指します。体内のホルモン、水分、塩分濃度、腎臓、神経系または血管の状態を含めた様々な要因で、血圧に影響が出ることがあります。たとえ血圧数値が危険なほど高いレベルに達していても、高血圧の症侯が見られない人が大部分です。早期の高血圧症で、頭部の鈍痛、目まいがあったり、通常より少し多めの鼻血が出る人も中にはいても、高血圧がひどくなるまでこうした症侯は起こらないのが典型的な例です。

当レポートでは、高血圧症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

高血圧症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • A1M Pharma AB
  • AbbVie Inc.
  • Ache Laboratorios Farmaceuticos S/A
  • Actelion Ltd
  • Afferent Pharmaceuticals, Inc.
  • Allergan Plc
  • Alnylam Pharmaceuticals, Inc.
  • Anacor Pharmaceuticals, Inc.
  • APT Therapeutics, Inc.
  • Arena Pharmaceuticals, Inc.
  • Ascendis Pharma A/S
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Bial - Portela & Ca, S.A.
  • Bio-inRen
  • BioRestorative Therapies, Inc.
  • Bristol-Myers Squibb Company
  • Cellceutix Corporation
  • Celsion Corporation
  • Celtaxsys, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • CJ HealthCare Corp.
  • Complexa, Inc.
  • Conatus Pharmaceuticals Inc.他

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8829IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H2 2016, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 32, 28, 26, 85 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 8 molecules, respectively.

Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hypertension Overview
  • Therapeutics Development
  • Hypertension - Therapeutics under Development by Companies
  • Hypertension - Therapeutics under Investigation by Universities/Institutes
  • Hypertension - Pipeline Products Glance
  • Hypertension - Products under Development by Companies
  • Hypertension - Products under Investigation by Universities/Institutes
  • Hypertension - Companies Involved in Therapeutics Development
  • Hypertension - Therapeutics Assessment
  • Drug Profiles
  • Hypertension - Dormant Projects
  • Hypertension - Discontinued Products
  • Hypertension - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hypertension, H2 2016
  • Number of Products under Development for Hypertension - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Hypertension - Pipeline by A1M Pharma AB, H2 2016
  • Hypertension - Pipeline by AbbVie Inc, H2 2016
  • Hypertension - Pipeline by Actelion Ltd, H2 2016
  • Hypertension - Pipeline by Afferent Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Anacor Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by AnGes MG Inc, H2 2016
  • Hypertension - Pipeline by APT Therapeutics Inc, H2 2016
  • Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Ascendis Pharma A/S, H2 2016
  • Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H2 2016
  • Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Bayer AG, H2 2016
  • Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2016
  • Hypertension - Pipeline by Biolab Farmaceutica Ltda, H2 2016
  • Hypertension - Pipeline by BioRestorative Therapies Inc, H2 2016
  • Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016
  • Hypertension - Pipeline by Cellceutix Corp, H2 2016
  • Hypertension - Pipeline by Celsion Corp, H2 2016
  • Hypertension - Pipeline by Celtaxsys Inc, H2 2016
  • Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016
  • Hypertension - Pipeline by CJ HealthCare Corp, H2 2016
  • Hypertension - Pipeline by Complexa Inc, H2 2016
  • Hypertension - Pipeline by Conatus Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Corion Biotech Srl, H2 2016
  • Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Cytokinetics Inc, H2 2016
  • Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016
  • Hypertension - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Hypertension - Pipeline by DiaMedica Inc, H2 2016
  • Hypertension - Pipeline by Eli Lilly and Company, H2 2016
  • Hypertension - Pipeline by Esperion Therapeutics Inc, H2 2016
  • Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Hypertension - Pipeline by Ferring International Center SA, H2 2016
  • Hypertension - Pipeline by Galectin Therapeutics Inc, H2 2016
  • Hypertension - Pipeline by Genextra Spa, H2 2016
  • Hypertension - Pipeline by Gilead Sciences Inc, H2 2016
  • Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Hypertension - Pipeline by Glenveigh Medical LLC, H2 2016
  • Hypertension - Pipeline by HanAll Biopharma Co Ltd, H2 2016
  • Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
  • Hypertension - Pipeline by HitGen LTD, H2 2016
  • Hypertension - Pipeline by Innopharmax Inc, H2 2016
  • Hypertension - Pipeline by Insmed Inc, H2 2016
  • Hypertension - Pipeline by INVENT Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Ionis Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016
  • Hypertension - Pipeline by Johnson & Johnson, H2 2016
  • Hypertension - Pipeline by JW Pharmaceutical Corp, H2 2016
  • Hypertension - Pipeline by Kowa Company Ltd, H2 2016
  • Hypertension - Pipeline by Leading BioSciences Inc, H2 2016
  • Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2016
  • Hypertension - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Hypertension - Pipeline by LFB SA, H2 2016
  • Hypertension - Pipeline by LG Life Science LTD, H2 2016
  • Hypertension - Pipeline by LinXis BV, H2 2016
  • Hypertension - Pipeline by Liquidia Technologies Inc, H2 2016
  • Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016
  • Hypertension - Pipeline by MannKind Corp, H2 2016
  • Hypertension - Pipeline by Mast Therapeutics Inc, H2 2016
  • Hypertension - Pipeline by Merck & Co Inc, H2 2016
  • Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2016
  • Hypertension - Pipeline by miRagen Therapeutics Inc, H2 2016
  • Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016
  • Hypertension - Pipeline by Morphogen-IX Ltd, H2 2016
  • Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016
  • Hypertension - Pipeline by Nippon Kayaku Co Ltd, H2 2016
  • Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2016
  • Hypertension - Pipeline by Novartis AG, H2 2016
  • Hypertension - Pipeline by Noxamet Ltd, H2 2016
  • Hypertension - Pipeline by Omeros Corp, H2 2016
  • Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2016
  • Hypertension - Pipeline by Pfizer Inc, H2 2016
  • Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Pluristem Therapeutics Inc, H2 2016
  • Hypertension - Pipeline by Polyphor Ltd, H2 2016
  • Hypertension - Pipeline by Proteo Inc, H2 2016
  • Hypertension - Pipeline by Pulmokine Inc, H2 2016
  • Hypertension - Pipeline by Quantum Genomics SA, H2 2016
  • Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by RedHill Biopharma Ltd, H2 2016
  • Hypertension - Pipeline by Respira Therapeutics Inc, H2 2016
  • Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2016
  • Hypertension - Pipeline by Sanofi, H2 2016
  • Hypertension - Pipeline by Selten Pharma Inc, H2 2016
  • Hypertension - Pipeline by Serodus ASA, H2 2016
  • Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016
  • Hypertension - Pipeline by Silence Therapeutics Plc, H2 2016
  • Hypertension - Pipeline by Simcere Pharmaceutical Group, H2 2016
  • Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2016
  • Hypertension - Pipeline by Suda Ltd, H2 2016
  • Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
  • Hypertension - Pipeline by The Medicines Company, H2 2016
  • Hypertension - Pipeline by Theravance Biopharma Inc, H2 2016
  • Hypertension - Pipeline by Toray Industries Inc, H2 2016
  • Hypertension - Pipeline by Torrent Pharmaceuticals Ltd, H2 2016
  • Hypertension - Pipeline by TSH Biopharm Corporation Ltd, H2 2016
  • Hypertension - Pipeline by United Therapeutics Corp, H2 2016
  • Hypertension - Pipeline by VBS Pharmaceuticals, H2 2016
  • Hypertension - Pipeline by Vectura Group Plc, H2 2016
  • Hypertension - Pipeline by VG Life Sciences Inc, H2 2016
  • Hypertension - Pipeline by Vicore Pharma AB, H2 2016
  • Hypertension - Pipeline by XORTX Pharma Corp, H2 2016
  • Hypertension - Pipeline by XuanZhu Pharma Co Ltd, H2 2016
  • Hypertension - Pipeline by Yuhan Corp, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hypertension - Dormant Projects, H2 2016
  • Hypertension - Dormant Projects (Contd..1), H2 2016
  • Hypertension - Dormant Projects (Contd..2), H2 2016
  • Hypertension - Dormant Projects (Contd..3), H2 2016
  • Hypertension - Dormant Projects (Contd..4), H2 2016
  • Hypertension - Dormant Projects (Contd..5), H2 2016
  • Hypertension - Dormant Projects (Contd..6), H2 2016
  • Hypertension - Dormant Projects (Contd..7), H2 2016
  • Hypertension - Dormant Projects (Contd..8), H2 2016
  • Hypertension - Dormant Projects (Contd..9), H2 2016
  • Hypertension - Dormant Projects (Contd..10), H2 2016
  • Hypertension - Dormant Projects (Contd..11), H2 2016
  • Hypertension - Dormant Projects (Contd..12), H2 2016
  • Hypertension - Dormant Projects (Contd..13), H2 2016
  • Hypertension - Dormant Projects (Contd..14), H2 2016
  • Hypertension - Dormant Projects (Contd..15), H2 2016
  • Hypertension - Dormant Projects (Contd..16), H2 2016
  • Hypertension - Dormant Projects (Contd..17), H2 2016
  • Hypertension - Dormant Projects (Contd..18), H2 2016
  • Hypertension - Dormant Projects (Contd..19), H2 2016
  • Hypertension - Dormant Projects (Contd..20), H2 2016
  • Hypertension - Dormant Projects (Contd..21), H2 2016
  • Hypertension - Dormant Projects (Contd..22), H2 2016
  • Hypertension - Dormant Projects (Contd..23), H2 2016
  • Hypertension - Dormant Projects (Contd..24), H2 2016
  • Hypertension - Dormant Projects (Contd..25), H2 2016
  • Hypertension - Discontinued Products, H2 2016
  • Hypertension - Discontinued Products (Contd..1), H2 2016
  • Hypertension - Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for Hypertension, H2 2016
  • Number of Products under Development for Hypertension - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top